Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:21 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,567 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control regimen Clear all
Terminated Phase 4 Interventional

Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens

NCT03560232
View directory record Official record
Conditions
Open Fracture, Post-Op Wound Infection
Interventions
Ceftriaxone, Ampicillin/sulbactam, Piperacillin/tazobactam, Cefazolin + Gentamicin, Clindamycin + Gentamicin
Drug
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Warren, Ohio • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Nov 1, 2026, 1:21 PM EST
Terminated Phase 2 Interventional Results available

A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption

NCT03115567
View directory record Official record
Conditions
Acneiform Rash, Papulopustular Eruption
Interventions
Triamcinolone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Nov 1, 2026, 1:21 PM EST
Active, not recruiting Phase 2 Interventional

NSAID Use After Robotic Partial Nephrectomy

NCT05842044
View directory record Official record
Conditions
Kidney Cancer, Renal Cancer, Renal Neoplasm
Interventions
Ketorolac, Acetaminophen, Oxycodone, Hydromorphone, Ibuprofen
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 99 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 1, 2026, 1:21 PM EST
Completed Not applicable Interventional

Burning Mouth Syndrome Mouth Guard Prospective Study

NCT04203134
View directory record Official record
Conditions
Burning Mouth Syndrome, Burning Mouth
Interventions
Mouthguard
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Nov 1, 2026, 1:21 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 1, 2026, 1:21 PM EST
Completed Phase 2 Interventional Results available

Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks

NCT05419505
View directory record Official record
Conditions
Edematous Fibrosclerotic Panniculopathy, Cellulite
Interventions
CCH-aaes, Antifibrinolytic Agent
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
13
States / cities
Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Nov 1, 2026, 1:21 PM EST
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

NCT02082522
View directory record Official record
Conditions
Hilar Cholangiocarcinoma
Interventions
Photodynamic therapy-Photofrin, Stenting procedure, Chemotherapy regimen
Drug · Procedure
Lead sponsor
Concordia Laboratories Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Nov 1, 2026, 1:21 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study to Examine the Effects of Cosmeceutical Therapy in Subjects Undergoing Full Facial Rejuvenation

NCT02726451
View directory record Official record
Conditions
Facial Rejuvenation With Neurotoxins and/or Hyaluronic Acid Fillers
Interventions
Basic Skin Care, Active Skin Care
Other
Lead sponsor
DeNova Research
Other
Eligibility
21 Years to 60 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Nov 1, 2026, 1:21 PM EST
Completed Phase 1 Interventional

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

NCT01170286
View directory record Official record
Conditions
Peanut Allergy
Interventions
Whole peanut extract, Placebo formulation
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
6 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2012 · Synced Nov 1, 2026, 1:21 PM EST
Not listed Phase 2 Interventional Accepts healthy volunteers

A 20-Week Study of a New Treatment for Men With Benign Prostatic Hyperplasia (BPH).

NCT00044226
View directory record Official record
Conditions
Prostatic Hyperplasia
Interventions
ML-04A
Drug
Lead sponsor
Milkhaus Laboratory
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
14
States / cities
Mobile, Alabama • Fair Oaks, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 1, 2026, 1:21 PM EST
Completed Phase 1 Interventional

Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement

NCT00454298
View directory record Official record
Conditions
Osteoarthritis
Interventions
AGG-523 (Aggrecanase Inhibitor)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
55 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Boston, Massachusetts • Newton, Massachusetts • Winchester, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2009 · Synced Nov 1, 2026, 1:21 PM EST
Completed Phase 1 Interventional Results available

StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns

NCT01437852
View directory record Official record
Conditions
Skin Wound, Burns, Trauma-related Wound
Interventions
StrataGraft Skin Tissue
Biological
Lead sponsor
Stratatech, a Mallinckrodt Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Phoenix, Arizona • Aurora, Colorado • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Nov 1, 2026, 1:21 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

NCT04431726
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
Emicizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
0 Months to 12 Months
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 1, 2026, 1:21 PM EST
Terminated Phase 2 Interventional Results available

A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection

NCT04398134
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H2158, Placebo, Entecavir (ETV)
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Pasadena, California • Redwood City, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Nov 1, 2026, 1:21 PM EST
Completed Phase 3 Interventional Results available

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects

NCT00529243
View directory record Official record
Conditions
HIV Infections
Interventions
raltegravir
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Anaheim, California • Hayward, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Nov 1, 2026, 1:21 PM EST
Completed Phase 3 Interventional Results available

A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00361335
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Golimumab, Methotrexate, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
20
States / cities
Peoria, Arizona • Aventura, Florida • Orlando, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Nov 1, 2026, 1:21 PM EST
Completed Phase 2 Interventional

A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

NCT00823680
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, RO5027838, RO5093151
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
35 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Nov 1, 2026, 1:21 PM EST
Recruiting Phase 2 Interventional

Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

NCT07062588
View directory record Official record
Conditions
Osteogenesis Imperfecta (OI)
Interventions
AGA2115, Placebo
Drug · Other
Lead sponsor
Angitia Incorporated Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • New Haven, Connecticut • Wilmington, Delaware + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 1, 2026, 1:21 PM EST
Not listed Phase 1Phase 2 Interventional

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

NCT03607643
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
Interventions
Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide
Drug
Lead sponsor
Leaf Vertical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Nov 1, 2026, 1:21 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Clinical Utility of Resistance Training for Improving Cardiovascular Disease Risk in Post-Menopausal Women

NCT03752060
View directory record Official record
Conditions
Cardiovascular Risk Factor, Menopause Related Conditions, Neuromuscular Function, Aerobic Capacity, Inflammation
Interventions
Resistance Exercise, Aerobic Exercise
Behavioral
Lead sponsor
Oklahoma State University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Nov 1, 2026, 1:21 PM EST
Not listed Phase 3 Interventional Accepts healthy volunteers

Office-based Vision Therapy for Improving Reading and Attention in Children With Convergence Insufficiency

NCT02207517
View directory record Official record
Conditions
Convergence Insufficiency
Interventions
Office-based vergence/accommodative therapy
Procedure
Lead sponsor
Salus University
Other
Eligibility
9 Years to 13 Years
Enrollment
311 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
8
States / cities
Birmingham, Alabama • Fullerton, California • Fort Lauderdale, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Nov 1, 2026, 1:21 PM EST
Completed Phase 2 Interventional

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

NCT01792050
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Docetaxel, Placebo, Indoximod, Paclitaxel
Drug · Other
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
28
States / cities
Gainesville, Florida • Tampa, Florida • Titusville, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Nov 1, 2026, 1:21 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03568318
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, Upadacitinib, Topical corticosteroids (TCS)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
59
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Nov 1, 2026, 1:21 PM EST
Not listed Not applicable Interventional Accepts healthy volunteers

Chronic Opioid Use in Low Back Pain and Lumbar Orthosis Intervention

NCT02241824
View directory record Official record
Conditions
Chronic Lower Back Pain, Chronic Opioid Use
Interventions
In-elastic lumbar brace, Elastic abdominal binder
Device
Lead sponsor
Geoffrey C. Garth
Other
Eligibility
20 Years to 72 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Nov 1, 2026, 1:21 PM EST